An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder

Open-label Phase IIa treatment study in patients with moderate to severe alcohol use disorder testing a single intranasal administration of BPL-003 combined with structured relapse-prevention psychological support; follow-up assessments extend to 12 weeks.

Primary outcomes focus on safety and tolerability; secondary and exploratory measures include pharmacodynamic effects and alcohol-use outcomes across the 12-week follow-up.